Current Status of Hormonal Therapy of Fibrocystic Breast Disease a
暂无分享,去创建一个
[1] L. Dogliotti,et al. Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic disease of the breast. , 1985, Hormone research.
[2] L. Dogliotti,et al. Thyroid hormone levels in human breast cyst fluid. , 1984, Acta endocrinologica.
[3] M. Breckwoldt,et al. Serum Prolactin Levels in Patients With Fibrocystic Breast Disease , 1984, Obstetrics and gynecology.
[4] G. Muccioli,et al. Presence and characterization of prolactin receptors in human benign breast tumours. , 1984, European journal of cancer & clinical oncology.
[5] M. Dowsett,et al. Endocrine effects of danazol in the treatment of endometriosis , 1984, British journal of obstetrics and gynaecology.
[6] M. Dowsett,et al. Prognostic significance of serum prolactin levels in advanced breast cancer. , 1983, British Journal of Cancer.
[7] L. Dogliotti,et al. Correlation between Levels of Dehydroepiandrosterone-Sulphate and Prolactin in Human Breast Cyst Fluid , 1982, Tumori.
[8] F. Kuttenn,et al. Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. , 1982, The Journal of clinical endocrinology and metabolism.
[9] R. Mansel,et al. CONTROLLED TRIAL OF THE ANTIGONADOTROPIN DANAZOL IN PAINFUL NODULAR BENIGN BREAST DISEASE , 1982, The Lancet.
[10] T. G. Muldoon. Interplay between estradiol and prolactin in the regulation of steroid hormone receptor levels, nature, and functionality in normal mouse mammary tissue. , 1981, Endocrinology.
[11] K J Ryan,et al. Danazol: endocrine pharmacology and therapeutic applications. , 1981, American journal of obstetrics and gynecology.
[12] P. Fioretti,et al. Inhibitory effect of the dopamine agonist bromocriptine on the postcastration gonadotrophin rise in women. , 1981, The Journal of clinical endocrinology and metabolism.
[13] K. Menon,et al. Estrogenic and antiestrogenic effects of danazol administration in studies of estradiol receptor binding. , 1981, American journal of obstetrics and gynecology.
[14] A. Malcolm. Production and processing of prolactin , 1981, Nature.
[15] S. Duck,et al. Danazol may cause female pseudohermaphroditism. , 1981, Fertility and sterility.
[16] B. Sherman,et al. Danazol: endocrine consequences in healthy women. , 1981, American journal of obstetrics and gynecology.
[17] H. Zimmerman,et al. DANAZOL AND LIVER DAMAGE , 1980, The Lancet.
[18] G. Chamness,et al. Danazol binding and translocation of steroid receptors. , 1980, American journal of obstetrics and gynecology.
[19] K. Menon,et al. Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation. , 1980, American journal of obstetrics and gynecology.
[20] E. Rebhan,et al. [Prolactin in serum and anamnestic data of women with cystic disease of the breast (author's transl)]. , 1980, Geburtshilfe und Frauenheilkunde.
[21] L. Dogliotti,et al. [Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline]. , 1979, Minerva medica.
[22] C. Laurell,et al. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. , 1979, The Journal of clinical endocrinology and metabolism.
[23] B. Sherman,et al. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. , 1979, The Journal of clinical investigation.
[24] I. Ricciardi,et al. Tamoxifen-induced regression of benign breast lesions. , 1979, Obstetrics and gynecology.
[25] G. Tolis,et al. Prolactin and Deficient Luteal Function , 1979, Obstetrics and gynecology.
[26] W. Dmowski,et al. Endocrine properties and clinical application of danazol. , 1979, Fertility and sterility.
[27] F. Halberg,et al. Circadian mesor-hyperprolactinemia in fibrocystic mastopathy. , 1979, The American journal of medicine.
[28] D. Graham,et al. Adult pre-sacral teratoma. , 1979, Postgraduate medical journal.
[29] J. Day. Clinical trials in the premenstrual syndrome , 1979 .
[30] L. Dogliotti,et al. Treatment of benign breast disease with bromocriptine , 1979, Journal of endocrinological investigation.
[31] F. Kuttenn,et al. [The treatment of benign pathological conditions of the breasts with progesterone and progestogens. The results according to the type of breast condition (260 case records) (author's transl)]. , 1978, Journal de gynecologie, obstetrique et biologie de la reproduction.
[32] W. Malarkey,et al. Disordered nocturnal prolactin regulation in women with breast cancer. , 1977, Cancer research.
[33] P. Franchimont,et al. The effect of danazol on anterior pituitary function. , 1977, Fertility and sterility.
[34] E. N. Cole,et al. Serum prolactin concentrations in benign breast disease throughout the menstrual cycle. , 1977, European journal of cancer.
[35] I. Mowszowicz,et al. Inadequate corpus luteal function in women with benign breast diseases. , 1977, The Journal of clinical endocrinology and metabolism.
[36] A. Hsueh,et al. REGULATION OF ESTROGEN RECEPTOR REPLENISHMENT BY PROGESTERONE * , 1977, Annals of the New York Academy of Sciences.
[37] V. Cararach,et al. Treatment of Fibrocystic Disease of the Breast With a Prolactin Inhibitor: 2-Br-Alpha- Ergocryptine (CB-154) , 1976, Obstetrics and gynecology.
[38] Lauersen Nh,et al. The effect of danazol in the treatment of chronic cystic mastitis. , 1976 .
[39] H. Rochefort,et al. Regulation of estrogen receptors in ovarian-dependent rat mammary tumors. I. Effects of castration and prolactin. , 1976, Endocrinology.
[40] T. Ranta,et al. HYPERPROLACTINÆMIA AND LUTEAL INSUFFICIENCY , 1976, The Lancet.
[41] A. Mcneilly,et al. A possible role for prolactin in control of steroid secretion by the human Graafian follicle , 1974, Nature.
[42] R. Greenblatt,et al. Clinical studies with an antigonadotropin-Danazol. , 1971, Fertility and sterility.